Syllabus: GS3/Science and Technology
In News
- Indian scientists at ICAR’s Central Rice Research Institute have developed a patented indigenous Genome-Editing(GE) technology using TnpB proteins as a compact alternative to the globally patented CRISPR-Cas systems.
| Do you know? – In May 2025, ICAR released two genome-edited rice varieties developed by Indian Institute of Rice Research (IIRR) and the Indian Agricultural Research Institute (IARI) – IIRR enhanced yields in Samba Mahsuri rice by editing the cytokinin oxidase 2 gene using CRISPR-Cas12a, while IARI improved drought and salinity tolerance in MTU-1010 (Cottondora Sannalu) by editing the DST gene with CRISPR-Cas9. – Despite these advances, commercial cultivation faces hurdles due to intellectual property restrictions on CRISPR-Cas technologies. |
TnpB or Transposon-associated proteins
- It acts as “molecular scissors,” and precisely cuts and modifies plant DNA, enabling desirable traits without introducing foreign genes.
- Unlike bulky Cas9 and Cas12a proteins, the hypercompact TnpB (408 amino acids) can be easily delivered into cells via viral vectors, bypassing tissue culture methods.
- ICAR secured a 20-year Indian patent in September 2025 and has filed for international protection, with adoption by plant breeders seen as the next critical step.
Features
- It has smaller proteins compared to CRISPR-Cas, reducing complexity and cost.
- It enables targeted DNA cuts and modifications for crop improvement.
- It reduces dependence on foreign proprietary technologies.
- It is designed for commercial application in crop breeding programs.
Benefits
- It cuts down licensing and royalty costs associated with foreign technologies.
- It is seen as a potential game-changer because CRISPR-Cas tools are heavily patented by the Broad Institute and Corteva, which may impose license fees on commercial cultivation of genome-edited (GE) crops.
- Indigenous tools could eliminate these IP barriers.
- It is seen as a potential game-changer because CRISPR-Cas tools are heavily patented by the Broad Institute and Corteva, which may impose license fees on commercial cultivation of genome-edited (GE) crops.
- It has the potential to deliver high-yield, climate-resilient, and pest-resistant varieties at lower costs.
- It strengthens India’s position in the $165.7 billion bioeconomy, projected to reach $300 billion by 2030.
- It enhances India’s ability to meet rising food demand sustainably.
- It positions India as a leader in affordable GE crop technologies.
Challenges
- India’s GE crops face strict biosafety and approval hurdles under the Plant Variety and Farmers’ Rights Protection Authority Act.
- Concerns around GM/GE crops persist among consumers and activists.
- Infrastructure Gaps: Need for advanced labs, trained personnel, and seed distribution networks.
Way Ahead
- India’s indigenous gene-editing technology offers a cost-effective alternative to global platforms, with the potential to democratize access to GE crops, enhance food security, and empower farmers.
- To fully realize its promise, there is a need for streamlining regulatory approvals while safeguarding biosafety and farmer rights.
- There is a need for building public trust through awareness, integrating efforts with national bioeconomy and innovation missions, fostering international collaboration.
Sources:IE
Previous article
India Becoming A Hub of Natural Farming
Next article
Global Methane Status Report 2025